[go: up one dir, main page]

WO2024158347A1 - Procédé d'enrobage pour soutenir une matrice osseuse allogène - Google Patents

Procédé d'enrobage pour soutenir une matrice osseuse allogène Download PDF

Info

Publication number
WO2024158347A1
WO2024158347A1 PCT/TH2023/050003 TH2023050003W WO2024158347A1 WO 2024158347 A1 WO2024158347 A1 WO 2024158347A1 TH 2023050003 W TH2023050003 W TH 2023050003W WO 2024158347 A1 WO2024158347 A1 WO 2024158347A1
Authority
WO
WIPO (PCT)
Prior art keywords
sustain
coating process
bone matrix
coating
allograft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TH2023/050003
Other languages
English (en)
Inventor
Chayarop SUPANCHART
Krissana TANGAMATAKUL
Donraporn DARANARONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiang Mai University
Original Assignee
Chiang Mai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiang Mai University filed Critical Chiang Mai University
Priority to PCT/TH2023/050003 priority Critical patent/WO2024158347A1/fr
Publication of WO2024158347A1 publication Critical patent/WO2024158347A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645—Connective tissue
    • A61L27/365—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D129/00—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Coating compositions based on hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Coating compositions based on derivatives of such polymers
    • C09D129/02—Homopolymers or copolymers of unsaturated alcohols
    • C09D129/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/08—Drying solid materials or objects by processes not involving the application of heat by centrifugal treatment
    • F26B5/10—Drying solid materials or objects by processes not involving the application of heat by centrifugal treatment the process involving freezing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/02—Methods for coating medical devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/08—Coatings comprising two or more layers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F116/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical
    • C08F116/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical by an alcohol radical
    • C08F116/04—Acyclic compounds
    • C08F116/06—Polyvinyl alcohol ; Vinyl alcohol

Definitions

  • Teeth are an important gastrointestinal organ that helps in digestion based on occlusion. Tooth loss, therefore, reduces the occlusion efficiency and may afflict gastrointestinal organs to exert themself on food digestion. In addition, it results in those with missing teeth losing their confidence in the social life. Tooth replacement, therefore, is important in that it helps restores the digestive and speech function. Occlusal reconstruction with dental prosthesis requires efficient masticatory force- supporting tissue apparatus, including gums and alveolar bone, that must be healthy and contain appropriate dimension.
  • the alveolar bone is an important structure that supports teeth and dental prosthesis. Insufficiencies of the alveolar bone often causes weakness and loss of the occlusion. In developed countries, most of urban people who lose their natural teeth prefer dental implant support prosthesis because of cost-efficient benefit of treatment. Approximately 50% of those who need prosthesis with dental implant were, however, found to require adjunctive treatment with bone grafting as well. In the past, bone graft used in dentistry was mostly taken from another own bone that usually causes multiple trauma, and extended operating time. Currently, bone substitutes taken from external origins, namely bone allografts, xenografts and alloplasts, are increasingly demanded. However, although xenografts or alloplasts are low-cost and simple to be prepared, they are unpopular because of their inferior biological properties.
  • bone allografts require freeze-dried process to eliminate microorganisms and minimize protein-induced immunogenicity. Therefore, due to cold- sterilization, bone biochemical and physical properties can be maintained as natural ones; for example, a bone stimulating agent e.g., BMP-2 (a member of TGF-beta family) can be maintained; together with hydrophilic property, which promotes cell or tissue adhesion superior to other bone substitutes do.
  • a bone stimulating agent e.g., BMP-2 (a member of TGF-beta family) can be maintained; together with hydrophilic property, which promotes cell or tissue adhesion superior to other bone substitutes do.
  • BMP-2 a member of TGF-beta family
  • hydrophilic property which promotes cell or tissue adhesion superior to other bone substitutes do.
  • Biodegradable polymer is a polymer that is degraded by hydrolysis in the surrounding tissue.
  • biodegradable polymers can be produced from natural products or synthetic materials.
  • biodegradable polymers have continuously been studied and developed, because of minimal tissue reaction. Interestingly, they are absorbed in the human body without toxic wastes in the body and can induce tissue regeneration.
  • Biodegradable polymers can, therefore, temporarily be used as a scaffold in tissue regeneration. Nevertheless, critical considerations in utilization of biodegradable polymers are the contamination from reactive residuals, e.g., monomer, stabilizers, initiators, or co-products during polymerization. Those contaminants, by safety, therefore, are essential to be checked, and discarded before using in clinic.
  • reactive residuals e.g., monomer, stabilizers, initiators, or co-products during polymerization. Those contaminants, by safety, therefore, are essential to be checked, and discarded before using in clinic.
  • biodegradable polymers are aliphatic polyesters with ester bonds that readily are degradable by hydrolysis in the body, and products from the degradation are water and carbon dioxide, which are non-toxic to the body and safely removable by bodily metabolism.
  • Sample medical polymers are poly(lactic acid) (PLA), poly(£-caprolactone) (PCL), poly(glycolic acid) (PGA) and so on, which are recognized by the United States Food and Drug Administration (FDA) as usable in patient treatment.
  • PDA poly(glycolic acid)
  • FDA United States Food and Drug Administration
  • WO2021159051A1 mentions a synthesized coated bone graft that undergoes freeze drying with electro spraying, where coating materials are a hydrophilic polymer being poly(lactide-co-glycolide) combined with therapeutic agents being bone stimulating agents, such as bone morphogenetic protein 2 (BMP-2), anti-fibrotic agents, antimicrobials, anti-inflammatory agents, and pro-angiogenesis agents.
  • bone stimulating agents such as bone morphogenetic protein 2 (BMP-2), anti-fibrotic agents, antimicrobials, anti-inflammatory agents, and pro-angiogenesis agents.
  • US patent publication number US20160310638A1 mentions a porous bone graft, consisting of a bone replacement material that can create adhesion with the natural bone (bioactive glass) in the form of biological material fiber granules and a bone graft composite for artificial roots with dispersing pores sized 100 nanometers to 1 millimeter, and possibly including a carrier material, such as collagen, phospholipid, carboxylmethylcellulose (CMC), glycerin, poly(ethylene glycol) (PEG), poly (lactic acid) (PLA) or poly(lactide-co-glycolide) (PLG).
  • a carrier material such as collagen, phospholipid, carboxylmethylcellulose (CMC), glycerin, poly(ethylene glycol) (PEG), poly (lactic acid) (PLA) or poly(lactide-co-glycolide) (PLG).
  • US patent publication number US20210283301A1 mentions a manufacturing procedure for a porous artificial root element, consisting of manufacture of biocompatible granules; mixing with a porogen, such as polyethylene, silicon, polystyrene, cellulose and so on; porogen compression onto the surface of biocompatible granules to create indentation on the surface of biocompatible granules; subsequent porogen removal using burning, panning, leaching, melt or evaporation; and subsequent granule coating with a biocompatible polypeptide mixed with a plasticizer using spraying followed by immersion-coating.
  • a porogen such as polyethylene, silicon, polystyrene, cellulose and so on
  • porogen compression onto the surface of biocompatible granules to create indentation on the surface of biocompatible granules
  • subsequent porogen removal using burning, panning, leaching, melt or evaporation and subsequent granule coating with a biocompatible polypeptide mixed with a plasticizer using spraying followed by immersion-
  • US patent publication number US20210178016A1 mentions polymers for coating graft bones for bone treatment, consisting of biocompatible and biodegradable polymers, namely polyesters, poly(vinyl alcohol) (PVA), poly(glycolic acid) (PGA), PLA, poly(lactide-co- glycolide) (PLG), chitin, chitosan or poly(ethylene glycol) (PEG).
  • Porogens include fibers formed from adsorbable materials, wherein graft bone surface has pores sized ⁇ 10 micrometers for facilitation of growth of osteoblasts and bone tissue. Also included are biomaterials, such as therapeutic agents, chemotherapeutic agents and so on.
  • US patent publication number US8178013B2 mentions bone graft with ideal mechanical strength that promotes bone treatment and counteracts degradation so that the bone regrows without risks to spread of diseases by coating with a biological material made from composite being a biological polymer, such as PGA, PLA, poly(lactide-co-glycolide) with diameter size of approximately 100-200 micrometers, and hydroxyapatite particles with diameter size less than 1 micrometer, onto bone surface.
  • the ratio of poly(lactide-co-glycolide) polymer to hydroxyapatite ranges from 1:2 to 2: 1.
  • coating with a biodegradable polymer is first performed by using a hydrophilic polymer to serve in joining and adhering to the surface of bone allografts followed by re-coating with another layer of biodegradable polymer for delaying bone degradation rates, where enhanced efficiency lies in the ability to customize degradation rates of coating polymers to the usage by adjusting ratios between utilized polymers.
  • the said coating will help promote the sustainability of replacement bones, delay the degradation of bones during the first 1-2 months of bone repair or bone graft to prepare for root support and so that the said bone allografts contain sufficient replacement bone quantities for progressive bone healing and can exist through the phase in which osteoblasts adhere for new bone healing, resulting in the bone graft having higher quality and more bone mass, and able to be attached to artificial roots more strongly. Additionally, the development of material coating method can be applied in controlled drug release further for enhancing the efficiency of osteopathy treatment in the future.
  • the coating process to sustain allogenic bone matrix consists of steps of preparation of hydrophilic polymer solution by dissolving a hydrophilic polymer in a solvent to a concentration between 0.1-2.0 % weight by volume; preparation of biodegradable polymer solution by dissolving a biodegradable polymer in a solvent to a concentration between 0.1-10.0 % weight by volume; the first coating of the allograft with the hydrophilic polymer so that the polymer joins and adheres to the surface of the allograft by adding the allograft to the hydrophilic polymer solution, mixing using centrifugation and then drying; and the subsequent second coating of the allograft with the biodegradable polymer by adding the allograft that has undergone the hydrophilic polymer coating to the biodegradable polymer solution, mixing using centrifugation and then drying.
  • the allograft is freeze-dried (freeze-dried bone allograft; FDBA) prior to coating with the polymers.
  • the goal of this invention is to provide a process for delaying the degradation of grafted bones for use as alveolar bones in dental disease treatment and as a support for both natural root and artificial root treatment, particularly the degradation in the initial phase of the bone graft so that osteoblasts can adhere and lead to osteoanagenesis without the replacement bone surface degrading too soon.
  • This invention selects bone allografts because they are more compatible with human tissues than alloplast bones are, enabling tissues or osteoblasts to adhere for ossification better, and coats the said bone allografts with a biodegradable polymer, which will help delay degradation rates so that the said bone allografts contain sufficient replacement bone quantities for progressive bone healing and can exist through the phase in which osteoblasts adhere for new bone healing, resulting in the bone graft having higher quality, more bone mass, and able to be attached to artificial roots more strongly. This helps improve the public health-related quality of life and increase access to dental disease treatment of patients efficiently.
  • Figure 1 shows analytical results of chemical structure on the surface of products using Fourier transform infrared spectroscopy (FTIR).
  • FTIR Fourier transform infrared spectroscopy
  • Figure 2 shows analytical results of surface quality using scanning electron microscope
  • Figure 3 shows biological degradation test results of biodegradable polymer-coated bones.
  • the coating process to sustain allogenic bone matrix comprises the following procedure.
  • the allograft is freeze-dried (freeze-dried bone allograft; FDBA) prior to coating.
  • hydrophilic polymer solution a hydrophilic polymer is dissolved in a solvent to a concentration between 0.1-2.0 % weight by volume.
  • the hydrophilic polymer can be selected from any one of poly(vinyl alcohol) or polyoxyethylene (20) sorbitan monooleate (or Polysorbate 80) or polyoxyethylene (20) sorbitan monostearate (or Polysorbate 60) or polyoxyethylene (20) sorbitan monopalmitate (or Polysorbate 40) or sorbitan monolaurate or sorbitan monopalmitate or sorbitan monostearate or sorbitan tristearate or sorbitan monooleate or combination thereof.
  • the solvent for dissolving the hydrophilic polymer can be selected from either water or alcohol or both.
  • the alcohol can be selected from either methanol or ethanol or both.
  • the most preferable solvent for dissolving the hydrophilic polymer is water.
  • biodegradable polymer solution a biodegradable polymer is dissolved in a solvent to a concentration between 0.1-10.0 % weight by volume.
  • the biodegradable polymer can be selected from any one of homopolyesters such as poly(L-lactide) (PLA) or poly(glycolide) (PLG) or poly(E-caprolactone) (PCL) or copolyesters such as poly(L-lactide-co-£-caprolactone) (PLC) or poly(L-lactide-co- glycolide) (PLG) or combination thereof.
  • homopolyesters such as poly(L-lactide) (PLA) or poly(glycolide) (PLG) or poly(E-caprolactone) (PCL)
  • copolyesters such as poly(L-lactide-co-£-caprolactone) (PLC) or poly(L-lactide-co- glycolide) (PLG) or combination thereof.
  • the preferable biodegradable polymer is a combination of PGA and PLA or PLG copolymer.
  • the preferable combination of PGA and PLA contains a higher proportion of PLA than that of PGA.
  • the preferable ratio between PLA and PGA is 70 to 30.
  • the solvent for dissolving the biodegradable polymer can be selected from any one of dichloromethane or chloroform or tetrahydrofuran or combination thereof.
  • the most preferable solvent for dissolving the biodegradable polymer is dichloromethane.
  • the allograft coating with the hydrophilic polymer is added to the hydrophilic polymer solution prepared in step A and mixed using centrifugation at a speed between 800-2,000 revolutions per minute at room temperature for 1-24 hours. Subsequently, the obtained product is dried for 8-24 hours.
  • drying in the step of the allograft coating with the hydrophilic polymer is performed using a vacuum dryer.
  • the allograft coating with the biodegradable polymer is added to the biodegradable polymer solution prepared in step B and mixed using centrifugation at a speed between 800-2,000 revolutions per minute at room temperature for 1-24 hours. Subsequently, the obtained product is dried for 8-60 hours.
  • drying in the step of the allograft coating with the biodegradable polymer is performed under vacuum for 8-24 hours.
  • drying in the step of the allograft coating with the biodegradable polymer is performed by freeze drying (or lyophilization) for 24-60 hours.
  • drying in the step of the allograft coating with the biodegradable polymer is performed under vacuum followed by freeze drying.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Materials Engineering (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un procédé d'enrobage pour soutenir une matrice osseuse allogène destinée à être utilisée comme os alvéolaire dans le traitement des maladies dentaires et comme support pour le traitement des racines, consistant en des étapes de préparation de l'allogreffe par lyophilisation, de préparation d'une solution polymère hydrophile, de préparation d'une solution polymère biodégradable, suivies de l'enrobage de l'allogreffe avec le polymère hydrophile afin que le polymère se joigne et adhère à la surface de l'allogreffe et de l'enrobage ultérieur de l'allogreffe avec le polymère biodégradable afin de retarder la dégradation de l'os.
PCT/TH2023/050003 2023-01-29 2023-01-29 Procédé d'enrobage pour soutenir une matrice osseuse allogène Ceased WO2024158347A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/TH2023/050003 WO2024158347A1 (fr) 2023-01-29 2023-01-29 Procédé d'enrobage pour soutenir une matrice osseuse allogène

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TH2023/050003 WO2024158347A1 (fr) 2023-01-29 2023-01-29 Procédé d'enrobage pour soutenir une matrice osseuse allogène

Publications (1)

Publication Number Publication Date
WO2024158347A1 true WO2024158347A1 (fr) 2024-08-02

Family

ID=91970944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TH2023/050003 Ceased WO2024158347A1 (fr) 2023-01-29 2023-01-29 Procédé d'enrobage pour soutenir une matrice osseuse allogène

Country Status (1)

Country Link
WO (1) WO2024158347A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117499A2 (fr) * 2006-04-05 2007-10-18 University Of Nebraska polymere bioresorbable, os reconstitue et procedes de formation
KR100794498B1 (ko) * 2007-04-23 2008-01-16 (주)코리아 본 뱅크 골조직의 진공 포장 공법
KR102193951B1 (ko) * 2020-05-25 2020-12-24 주식회사 울트라브이 필러용 생분해성 고분자 미세입자의 제조 방법, 및 이를 포함하는 주사제의 제조 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117499A2 (fr) * 2006-04-05 2007-10-18 University Of Nebraska polymere bioresorbable, os reconstitue et procedes de formation
KR100794498B1 (ko) * 2007-04-23 2008-01-16 (주)코리아 본 뱅크 골조직의 진공 포장 공법
KR102193951B1 (ko) * 2020-05-25 2020-12-24 주식회사 울트라브이 필러용 생분해성 고분자 미세입자의 제조 방법, 및 이를 포함하는 주사제의 제조 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVIDOFF SHERRY N, CALL BRENT P, HOGREBE PAUL C, GRAINGER DAVID W, BROOKS AMANDA E, : "A ROBUST METHOD TO COAT ALLOGRAFT BONE WITH A DRUG-RELEASING POLYMER SHELL", PRESENTED AT ROCKY MOUNTAIN BIOENGINEERING SYMPOSIUM & INTERNATIONAL ISA BIOMEDICAL SCIENCES INSTRUMENTATION SYMPOSIUM, 1 April 2010 (2010-04-01), pages 1 - 6, XP093198448 *

Similar Documents

Publication Publication Date Title
CN1136922C (zh) 可植入的可生物再吸收的膜及其制备方法
Liao et al. The degradation of the three layered nano-carbonated hydroxyapatite/collagen/PLGA composite membrane in vitro
US7326426B2 (en) Compositions and medical devices utilizing bioabsorbable liquid polymers
EP1430917B1 (fr) Compositions et dispositifs médicaux utilisant des cires polymériques bioabsorbables
US7030127B2 (en) Composition and medical devices utilizing bioabsorbable polymeric waxes
Xue et al. In vitro and in vivo evaluation of chitosan scaffolds combined with simvastatin-loaded nanoparticles for guided bone regeneration
Jang et al. PCL/HA hybrid microspheres for effective osteogenic differentiation and bone regeneration
JP2000516839A (ja) 皮下注入用、あるいは皮内注入用インプラント
CN1929880A (zh) 包含多孔载体和至少一种吡咯烷酮的骨移植材料、其生产方法和植入物
JP2004523291A (ja) 医療用インプラントの製造方法
EP2793962A1 (fr) Procédé de modification de la morphologie de surface d'un dispositif médical
Ma et al. Periodontal guided tissue regeneration membranes: limitations and possible solutions for the bottleneck analysis
Thuaksuban et al. Biodegradable polycaprolactone-chitosan three-dimensional scaffolds fabricated by melt stretching and multilayer deposition for bone tissue engineering: assessment of the physical properties and cellular response
Bastami et al. Addition of Bone‐Marrow Mesenchymal Stem Cells to 3D‐Printed Alginate/Gelatin Hydrogel Containing Freeze‐Dried Bone Nanoparticles Accelerates Regeneration of Critical Size Bone Defects
JP7543300B2 (ja) プロリンリッチペプチドを含む改良型骨インプラントマトリクスおよびその調製方法
KR20240113974A (ko) 하이브리드 조직 공학 구조물
WO2024158347A1 (fr) Procédé d'enrobage pour soutenir une matrice osseuse allogène
Saptaji et al. Review of the Potential use of Poly (lactic-co-glycolic acid) as Scaffolds in Bone Tissue Recovery
Salles et al. In vitro and in vivo evaluation of electrospun membranes of poly (ε-caprolactone) and poly (rotaxane)
Ojha et al. A Review on the Application of Poly Lactic Co-Glycolic Acid in Bone Grafts
Passi et al. Plain and drug loaded polyphosphazene membranes and microspheres in the treatment of rabbit bone defects
Thomas et al. An application of decellularized membrane as guided tissue regeneration
RU2831611C2 (ru) Усовершенствованная матрица для костного имплантата, содержащая богатый пролином пептид, и способ ее изготовления
Suttiat Fabrication of poly (lactic acid)/poly (butylene adipate-co-terephthalate) cell scaffold for socket preservation
Barros et al. Polymers in Guided Bone Regeneration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23918798

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE